

Patent Updates

Suven Life Sciences secures Product Patents in Australia, EAPO, EPO, New Zealand, Thailand and USA

HYDERABAD, INDIA (September 11, 2025) – Suven Life Sciences Ltd secures one (1) product patent from Australia (2023207844), one (1) product patent from EAPO (50640), one (1) product patent from EPO (EP4069231), two (2) product patents from New Zealand (788973 & 813281), one (1) product patent from Thailand (110406) and one (1) product patent from USA (12338236) corresponding to the new Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2043, 2043, 2040, 2040, 2043, 2034 and 2043 respectively.

The granted claims of the patents include the class of selective 5HT4, 5HT6 and Multimodal compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Excessive Daytime Sleepiness in Narcolepsy Huntington's disease, Parkinson and Schizophrenia etc.

Disclaimer and Risk Statement:

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.